M&A / Property

RAMM Pharma Corp. Receives Minority Shareholder Approval for Proposed Investment Transaction with The Global South S.A.S.

By The Northwire Desk — AI Analysis Nov 13, 2025 · 17:00 RAMM · 0.09 Ramm Pharma Corp.

RAMM · Price

RAMR Pharma’s minority shareholders approved a proposed $5 million equity investment in The Global South S.A.S., giving RAMR an initial 10% stake.
The deal includes a five‑year call option for RAMR to acquire up to an additional 15% (total 25%) at a future post‑money valuation of US$400 million.
Completion is contingent on financing, definitive agreements, customary closing conditions and regulatory approvals; the company currently lacks funds to close the transaction.

Transaction Structure:
Initial cash investment: US$5 million for a 10% equity interest in The Global South S.A.S. (post‑investment valuation US$50 million).
Call option: Right to purchase up to an additional 15% equity (bringing total ownership to 25%) at a future post‑money valuation of US$400 million.
Option Terms:
Term length: 5 years starting upon successful completion of the initial $5 M investment.
Exercise price tied to the specified future valuation; no amount disclosed for the option exercise.
Shareholder Approval:
Approved at a Special Meeting of Shareholders on November 12, 2025 by RAMR’s minority shareholders.
Financing Status:
Company does not currently have sufficient funds to complete the $5 M investment and is evaluating financing alternatives.
Closing Conditions:
Execution of definitive documentation, customary closing conditions, and receipt of all required regulatory approvals.
Forward‑Looking Statements:
The release contains extensive forward‑looking language regarding the transaction, potential growth, and associated risks.

(No direct quotes were provided in the release.)

More from Ramm Pharma Corp.